Exact Sciences Co. (NASDAQ:EXAS) EVP Brian Baranick Sells 929 Shares

Exact Sciences Co. (NASDAQ:EXAS) EVP Brian Baranick sold 929 shares of the company’s stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $70.00, for a total value of $65,030.00. Following the sale, the executive vice president now owns 13,687 shares of the company’s stock, valued at $958,090. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Exact Sciences Stock Performance

Shares of EXAS opened at $70.09 on Friday. The stock has a 50-day moving average of $57.32 and a two-hundred day moving average of $55.84. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.98 and a current ratio of 2.17. The stock has a market cap of $12.93 billion, a P/E ratio of -53.10 and a beta of 1.26. Exact Sciences Co. has a one year low of $40.62 and a one year high of $79.62.

Exact Sciences (NASDAQ:EXAS) last released its earnings results on Wednesday, July 31st. The medical research company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.28. Exact Sciences had a negative return on equity of 4.97% and a negative net margin of 6.70%. The firm had revenue of $699.26 million during the quarter, compared to the consensus estimate of $690.02 million. During the same quarter in the previous year, the company posted ($0.45) earnings per share. The company’s revenue was up 12.4% compared to the same quarter last year. As a group, research analysts predict that Exact Sciences Co. will post -0.87 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Jefferies Financial Group began coverage on shares of Exact Sciences in a report on Monday, June 3rd. They issued a “buy” rating and a $75.00 target price for the company. Canaccord Genuity Group reissued a “buy” rating and set a $75.00 target price on shares of Exact Sciences in a research report on Friday, September 13th. BTIG Research lowered their target price on shares of Exact Sciences from $80.00 to $70.00 and set a “buy” rating for the company in a research note on Wednesday, June 26th. Stifel Nicolaus reduced their price target on Exact Sciences from $100.00 to $82.00 and set a “buy” rating on the stock in a research report on Thursday, August 1st. Finally, Benchmark lowered their price objective on Exact Sciences from $91.00 to $67.00 and set a “buy” rating for the company in a research report on Thursday, August 1st. One investment analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $78.14.

Institutional Trading of Exact Sciences

Several large investors have recently made changes to their positions in EXAS. Vanguard Group Inc. lifted its position in Exact Sciences by 1.0% during the first quarter. Vanguard Group Inc. now owns 17,740,092 shares of the medical research company’s stock valued at $1,225,131,000 after purchasing an additional 180,341 shares during the period. Capital World Investors grew its position in Exact Sciences by 74.4% during the 1st quarter. Capital World Investors now owns 13,025,313 shares of the medical research company’s stock worth $899,528,000 after purchasing an additional 5,557,168 shares during the period. Artisan Partners Limited Partnership raised its stake in shares of Exact Sciences by 12.8% during the 4th quarter. Artisan Partners Limited Partnership now owns 4,470,278 shares of the medical research company’s stock valued at $330,711,000 after buying an additional 508,764 shares during the last quarter. William Blair Investment Management LLC acquired a new position in shares of Exact Sciences in the 2nd quarter valued at about $163,896,000. Finally, Champlain Investment Partners LLC boosted its stake in shares of Exact Sciences by 175.3% in the first quarter. Champlain Investment Partners LLC now owns 2,258,235 shares of the medical research company’s stock worth $155,954,000 after buying an additional 1,438,010 shares during the last quarter. 88.82% of the stock is owned by hedge funds and other institutional investors.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.